Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Multiple Myeloma × Tablets × Clear all

Phase

Status

Withdrawn 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Uterine Neoplasms 1 Pregnancy Complications 1 Nasopharyngeal Neoplasms 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Leiomyoma 1 Infertility, Female 1 Genetic Diseases, Inborn 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Dexamethasone 105 Lenalidomide 73 daratumumab 54 Bortezomib 48 carfilzomib 35 pomalidomide 32 Calcium Dobesilate 30 Cyclophosphamide 25 isatuximab 19 belantamab mafodotin 16 Biopsy 13 Specimen Handling 12 dexamethasone acetate 11 dexamethasone 21-phosphate 11 Melphalan 11 selinexor 10 ixazomib 10 auricularum 10 Magnetic Resonance Spectroscopy 10 fludarabine 9 iberdomide 8 elotuzumab 8 talquetamab 6 nirogacestat 6 fludarabine phosphate 6 trametinib 5 Thalidomide 5 Etoposide 5 venetoclax 4 tocilizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04717700 2025-03-18

SABLe

Odense University Hospital

Phase 2 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡